KIN stock holds steady as Kyntra Bio prepares new earnings update

Published on 09/02/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

KIN stock represents Kyntra Bio, a biotech player preparing to report second quarter 2026 results, with investors watching market data and recent guidance closely.

KIN, US4945761006, Illustration mit AI erstellt.

KIN stock reflects the performance of Kyntra Bio, Inc. (ISIN US4945761006), a biotechnology company whose shares recently traded at 7.91 USD on the CBOE, signaling a modest decline of 1.37% over a five day window as of September 2, 2026 according to market data compiled by a stock portal.

Latest price and market context

According to data reported by MarketScreener, Kyntra Bio stock was quoted at 7.91 USD with a five day change of negative 1.37% and a year to date performance of negative 8.87%, offering investors a snapshot of the recent trading range as of September 2, 2026.

The same overview shows that Kyntra Bio trades on a CBOE venue in the United States, which anchors the stock in the broader American biotech universe and gives investors direct exposure to developments in the company’s pipeline and financial results.

Upcoming earnings and recent fundamentals

In a schedule item dated August 6, 2026 and highlighted by the same MarketScreener listing, Kyntra Bio announced plans to report its second quarter 2026 financial results, making Q2 2026 the most recent reporting period investors can expect to analyze in detail.

While detailed Q2 2026 figures are not yet broken out in the snapshot, a prior update summarizing the company’s performance indicated that Kyntra Bio generated revenue in the tens of millions of USD range in fiscal year 2025 and used that base to support ongoing research and development; these historical numbers are relevant primarily as a benchmark and not as the current picture of the business.

For investors, the key current fundamental focus is the upcoming Q2 2026 report and how metrics such as revenue growth, operating margin, and cash burn compare with fiscal year 2025 levels, particularly if the company manages to narrow losses or accelerate top line growth in a way that supports a more sustainable trajectory.

Go deeper

More background on KIN stock

For detailed filings and historical figures on Kyntra Bio, investors can consult issuer specific information and related news on the instrument associated with ISIN US4945761006.

More articles on KIN stock Investor Relations

Biotech focus and key product direction

Kyntra Bio positions itself in the biotech space with a focus on therapies that address unmet medical needs, leveraging proprietary platforms and collaborations to build a differentiated pipeline.

The company’s strategy emphasizes development stage assets that can move through clinical trials efficiently, with management highlighting the importance of balancing investment in new studies against the company’s cash position and available funding sources.

KIN stock for investors

Based on the quote snapshot as of September 2, 2026, Kyntra Bio stock traded at 7.91 USD on a CBOE venue, reflecting the latest available price information for KIN and framing expectations for upcoming Q2 2026 financial results.